Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04395066
Other study ID # 2018KY149
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date June 1, 2020
Est. completion date June 1, 2023

Study information

Verified date May 2020
Source Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

Serious pneumonia is a serious inflammation of the lungs caused by various pathogens, resulting in severe bacteraemia or toxemia, which in turn causes blood pressure drop, shock, blurred consciousness, restlessness, delirium and coma, etc., and requires intensive care and treatment in intensive care unit (ICU) because of its seriousness. There is an upward trend in the number of clinically immunosuppressed host patients, including long-term use of glucocorticoids for rheumatoid immune diseases and kidney diseases, tumor chemotherapy, organ transplantation, etc. A huge risk for these patients is the diagnosis and treatment of infections, especially lung infections. We have previously observed a significant increase in mortality from severe pneumonia in immunosuppressed patients, and our recent analysis of 204 patients with novel coronavirus pneumonia found that low lymphatic counts, immunosuppression, etc. were independent risk factors for death in patients. Early diagnosis and timely treatment are the main means to reduce the mortality rate of severe pneumonia. CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases, both of which mediate the downstream action of all three complement activation pathways, and CD55 protects host cells from complement attack. Our previous study found that CD55 was significantly elevated in patients with severe pneumonia. Therefore, this project proposes "Early diagnosis of severe pneumonia based on combination of biomarkers with new generation pathogenesis and early clinical manifestations". It is proposed to validate the predictive effects of recently discovered markers such as CD55, HBP and CD64 on severe pneumonia through prospective single-center clinical studies, explore the establishment of new predictive models for early diagnosis of severe pneumonia, and optimize the diagnosis and treatment strategy of severe pneumonia, and provide new ideas for accurate treatment of severe pneumonia.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 171
Est. completion date June 1, 2023
Est. primary completion date June 1, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- ? Age = 18 years, = 75 years, male or female

- Patients diagnosed with severe pneumonia ? Immunosuppressed patients

- Patient informed consent

Exclusion Criteria:

- ? Pregnant women, lactating women and women who are at risk of pregnancy.

- Patients with malignant neoplasms that have metastasized extensively and are expected to have a short survival period.

- Patients with obstructive pneumonia and interstitial fibrosis due to lung tumours.

- refusal of the patient or the patient's family to participate in the study.

- Refusal of invasive mechanical ventilation and tracheal intubation by the patient or the patient's family.

Study Design


Intervention

Diagnostic Test:
CD55
CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases, both of which mediate downstream actions of all three complement activation pathways, and CD55 protects host cells from complement attack.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Outcome

Type Measure Description Time frame Safety issue
Primary Number of patient diagnosed with severe pneumonia within 28 days 28 days
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05845112 - Start Taking Action For TB Diagnosis
Not yet recruiting NCT05889312 - Assessing Cancer Treatment Response to Therapy Using 18F-FSPG PET
Completed NCT01194557 - Introducing Rapid Diagnostic Tests Into the Private Health Sector N/A
Completed NCT04257955 - COMMUNIcation and Patient Engagement at Diagnosis of PAncreatic CAncer
Recruiting NCT05698212 - Proof of Concept Study to Eval MetriDx Lab-developed Test to Identify Endometriosis-specific Bio Markers Phase 2
Recruiting NCT03372330 - Peripheral Artery Disease and Sepsis Outcomes N/A
Active, not recruiting NCT06134011 - A Multi-omics-based Metabolic Typing Study of Gastric Cancer
Recruiting NCT06289803 - The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery N/A
Not yet recruiting NCT06025240 - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Not yet recruiting NCT05464576 - Tumor Staging T of Bladder Tumours: Correlation of MRI and Anatomopathologic Analysis N/A
Completed NCT06185127 - Dexmedetomidine-ketamine Combination Versus Fentanyl-midazolam During Bronchoscopy Phase 3
Recruiting NCT05824442 - Evaluation of a New Multiplex Quantitative PCR Technique for the Diagnosis of Echinococcosis N/A
Not yet recruiting NCT06463223 - HIBOC = Hepatic Imaging Biomarkers in Obese Children
Not yet recruiting NCT06072820 - Analytical Evaluation of the Endotest® Diagnostic N/A
Recruiting NCT05587114 - Comparision of Various Biomarkers Between Peripheral and Pulmonary Blood
Recruiting NCT06230458 - Fractional Exhaled Nitric Oxide (FeNO)- Test as add-on Test in the Diagnostic Work-up of Asthma N/A
Not yet recruiting NCT05948410 - How Does the Mood of the Patients Change Before and After the Invasive Urodynamic Study?
Not yet recruiting NCT05947565 - Patient Position and Invasive Urodynamic Study Results in Males N/A
Not yet recruiting NCT04490746 - Identifcation of Biomarkers for Active Pulmonary Tuberculosis
Completed NCT03381131 - Chinese Version of Fibromyalgia Criteria and Severity Scales Study